Cintas (NASDAQ:CTAS) reported quarterly earnings of $2.81 per share which beat the analyst consensus estimate of $2.67 by 5.24 percent. This is a 13.77 percent increase over earnings of $2.47 per share from the same period last year. The company reported quarterly sales of $2.08 billion which beat the analyst consensus estimate of $2.01 billion by 3.23 percent. This is a 13.02 percent increase over sales of $1.84 billion the same period last year.
Regeneron/Sanofi’s Largest Selling Drug Dupixent Scores FDA Approval For Infants With Esophagus Inflammation
FDA approves Dupixent (dupilumab) by Regeneron/Sanofi for pediatric eosinophilic esophagitis treatment. Breakthrough treatment for young patients.
